Related Experiment Video
Updated: Jul 10, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left atrial appendage closure for stroke prevention in atrial fibrillation patients: A promise that came true
Xi Jiang1, Qingsong Xiong1, Yuehui Yin1
1Department of Cardiology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Insights
Left atrial appendage closure (LAAC) offers a stroke prevention alternative to anticoagulation for atrial fibrillation (AF) patients, especially those at high bleeding risk. Ongoing research addresses remaining concerns regarding efficacy and safety.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Device Innovation
Background:
- Atrial fibrillation (AF) management necessitates stroke risk reduction due to high associated morbidity and mortality.
- Oral anticoagulation is standard but carries bleeding risks, creating a need for alternatives.
- The left atrial appendage (LAA) is implicated as the primary thrombus source in AF patients.
Purpose of the Study:
- To review current knowledge on left atrial appendage closure (LAAC) as a stroke prevention strategy in AF.
- To highlight advancements in LAAC safety, efficacy, and device technology.
- To identify and discuss future directions for LAAC, addressing existing challenges.
Main Methods:
- Comprehensive literature review of existing studies on LAAC.
- Analysis of current data on LAAC safety and efficacy profiles.
- Identification of device-related complications and procedural optimization needs.
Main Results:
- LAAC has shown significant advancements in safety and efficacy for stroke prevention in AF.
- Concerns persist regarding the robustness of efficacy data and device-related complications.
- Procedural optimization is crucial for improving LAAC outcomes.
Conclusions:
- LAAC is a promising alternative to oral anticoagulation for stroke prevention in select AF patients.
- Further research is needed to solidify efficacy data and refine procedural techniques.
- Addressing current limitations will enhance LAAC's role in managing AF-related stroke risk.
Abstract:
Anticoagulation therapy plays a crucial role in the management of atrial fibrillation (AF), considering the high morbidity and mortality of AF-related ischemic strokes. With the plausible hypothesis that left atrial appendage is the main source of thrombus in AF patients, left atrial appendage closure (LAAC) has been regarded as a potential substitute to oral anticoagulation in order to meet the unmet needs for stroke prevention, particularly in patients with high bleeding risk. Notable advancements in safety, efficacy, and device innovation have been made in recent years, albeit concerns still remain regarding the insufficient efficacy data, device-related complications, and the need for procedural optimization. We aim to review current knowledge about LAAC and provide potential future directions for the remaining key issues.
